Welcome to our dedicated page for Cellebrite DI Ltd. news (Ticker: $CLBTW), a resource for investors and traders seeking the latest updates and insights on Cellebrite DI Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cellebrite DI Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cellebrite DI Ltd.'s position in the market.
Cellebrite (NASDAQ: CLBT) announced its Q1 2024 results, reporting a 27% year-over-year increase in Annual Recurring Revenue (ARR) to $331.8 million. Q1 2024 revenue rose by 26% to $89.6 million, driven by a 29% growth in subscription revenue. The company recorded a GAAP net loss of $71.4 million and a non-GAAP net income of $16.9 million. Adjusted EBITDA stood at $17.6 million with a 19.7% margin. CEO Yossi Carmil emphasized the global expansion and profitability improvements, noting the positive reception of new products like the Inseyets digital forensics software. The company reaffirmed its outlook for 2024, expecting ARR between $380 million and $400 million, and revenue between $370 million and $380 million for the full year.
Cellebrite (NASDAQ: CLBT), a global leader in digital investigative solutions, announced its participation in several investor conferences from May 26 to June 5, 2024. The company will engage in various formats, including fireside chats, 1x1 meetings, and presentations.
Key dates include May 26 at the Oppenheimer 25th Annual Israeli Conference, May 29 at the Craig-Hallum Institutional Investor Conference, May 30 at the TD Cowen 52nd Annual Technology, Media & Telecom Conference, and June 5 at the William Blair 44th Annual Growth Stock Conference.
Cellebrite executives like Dana Gerner (CFO), Andrew Kramer (VP), and Yossi Carmil (CEO) will present at these events. The conferences are opportunities for the company to highlight its digital investigative solutions and connect with investors.
